WINSTON-SALEM, N.C. -- (BUSINESS WIRE) -- Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that it will report financial results for the first quarter of 2014 on the morning of Wednesday, May 7, 2014, before the U.S. financial markets open.
Management will discuss the company’s first quarter financial results, provide a business update, and discuss expectations for the future via conference call at 8:30 a.m. Eastern Daylight Time on Wednesday, May 7, 2014. The conference call may be accessed by dialing 877.474.9503 for domestic participants and 857.244.7556 for international callers (the passcode for the call is 72389638).
A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay through the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the call.
Targacept is developing an advanced clinical pipeline of NNR Therapeutics™ to treat patients suffering from serious nervous system and gastrointestinal/genitourinary diseases and disorders. Many diseases arise from abnormalities in signaling within and between the brain and other organ systems such as the bladder and the GI tract. Targacept’s NNR Therapeutics™ have the potential to normalize these signaling pathways to provide significant medical benefit. Targacept is dedicated to building health and restoring independence for patients. For more information, please visit www.targacept.com.